Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Express Scripts
Harvard Business School
McKesson
Merck

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Asimadoline

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Asimadoline?

Asimadoline is an investigational drug.

There have been 7 clinical trials for Asimadoline. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2010.

The most common disease conditions in clinical trials are Irritable Bowel Syndrome, Syndrome, and Pruritus. The leading clinical trial sponsors are Tioga Pharmaceuticals, RTI Health Solutions, and Mayo Clinic.

There are two hundred and thirty-four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Asimadoline
TitleSponsorPhase
Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic DermatitisTioga PharmaceuticalsPhase 2
A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male VolunteersTioga PharmaceuticalsPhase 1
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)RTI Health SolutionsPhase 3

See all Asimadoline clinical trials

Clinical Trial Summary for Asimadoline

Top disease conditions for Asimadoline
Top clinical trial sponsors for Asimadoline

See all Asimadoline clinical trials

US Patents for Asimadoline

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Asimadoline   Start Trial Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof   Start Trial
Asimadoline   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Asimadoline   Start Trial Synthetic peptide amides and dimers thereof Cara Therapeutics, Inc. (Stamford, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Asimadoline

Drugname Country Document Number Estimated Expiration Related US Patent
Asimadoline European Patent Office 3324975 2035-07-22   Start Trial
Asimadoline World Intellectual Property Organization (WIPO) 2017015309 2035-07-22   Start Trial
Asimadoline Australia 2014274812 2033-06-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Johnson and Johnson
Colorcon
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.